Abstract: Among adult participants, factors associated with preexisting M184 V/I included other resistance, Black race, Hispanic/Latinx ethnicity, lower baseline CD4 cell count, advanced HIV disease, longer duration of antiretroviral therapy, and greater number of prior third agents.
Abstract: At last on-treatment visit, 98% (179/182) with preexisting M184 V/I and 99% (2012/2034) of all B/F/TAF-treated participants had HIV-1 RNA <50 copies/mL, with no treatment-emergent resistance to B/F/TAF.
Abstract: CONCLUSIONS: M184 V/I was detected in 10% of virologically suppressed clinical trial participants at study baseline.
Abstract: Most substitutions were M184 V (n = 161) or M184 V/I mixtures (n = 10).
Abstract: OBJECTIVE: We in
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Discussion: A combination of RAM similar to those found in this case (M184V, K65R, V108I and E138A) has not been reported in PrEP users.
Discussion: Although theoretically possible, it is unlikely that the short-term and limited drug exposure was sufficient to select for both M184V and K65R, with only few M184V mutations, and even more rarely K65R, described in the literature.
Discussion: However, six cases of HIV infection despite PrEP use have been described previously; in two cases both M184V and K65R were identified.
Discussion: Possible explanations for the PrEP failure in our
Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.
PMID: 35107140
2022
The Journal of antimicrobial chemotherapy
Abstract: Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), D67DN (30.3%), G190A (28.6%) and A98G (26.8%).
Table: M184V
Discussion: Some of the most common mutations in this study were M184V, K103N, Y181C and G190A, which occurred at similar frequencies to those reported in studies from other SSA and Tanzanian settings.
Discussion: The presence of M184V was in line with a study done in Tanzania that showed a high prevalence of this mutation among
Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
PMID: 35302390
2022
AIDS research and human retroviruses
Abstract: M184V/I, K103N/S and Y181C were the most commonly occurring mutations, seen in 76%, 51% and 36% children.
Abstract: At BL, K103N (5), E138A/G (4) and M184V (3) were the most common mutations.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
PMID: 35301540
2022
The Journal of infectious diseases
Abstract: Nine women in the TDF/FTC arm had nonnucleoside reverse-transcriptase inhibitor resistance; 1 had the nucleoside reverse-transcriptase inhibitor resistance mutation, M184V.
Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.
Abstract: The predominant DRMs for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs).
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
PMID: 35192922
2022
Journal of clinical epidemiology
Abstract: Patients failing first-line ART including emtricitabine or lamivudine showed high levels of the M184V/I mutation after two years: 75.7% (95% Credibility Interval [CrI] 61.9%-88.9%) if combined with tenofovir, and 72.1% (95% CrI 56.8%-85.9%) with zidovudine.
High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
Discussion: Interestingly, the M184V variant was not common (<1%, not shown) in this cohort.
Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.
PMID: 35164871
2022
Journal of medical case reports
Conclusion: At the point of CSF escape diagnosis, the CD4 cell count was 180 cells/mm3, and both plasma and CSF harbored the same NRTI M184V mutation.
Conclusion: The NRTI M18
Conclusion: The HIV-1 pol gene genotypic resistance analysis showed development of the NRTI M184V mutation, and NNRTI K103N and E138EK mutations in plasma, respectively.
Discussion: Cerebrospinal fluid escape is seen after more than 15 years of HIV infection, previous low-level viremia, and the presence of M184V/I mutations in the CSF.
Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Result: M184V (0.23%, 2/865) was the most common nucleoside reverse transcriptase inhibitors (NRTIs) related mutation followed by T69D (0.12%, 1/865) and T69G (0.12%, 1/865).
Result: NGS was more sensitive in detecting low-frequency mutations and a total of 4 mutations were detected by NGS but missed by Sanger sequencing which including M184V (1.31%), K65E (3.72%), E138G (1.21%), and Y188C (1.04%).
HIV mutation literature information.
PMID: 
2022
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT